Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam

Lauren K Flynt¹, Michael P Veve^{1

2}, Linoj P Samuel¹, Robert J Tibbetts³

Affiliations

¹ Henry Ford Hospital, Detroit, Michigan, USA.
² Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
³ Henry Ford Hospital, Detroit, Michigan, USA rtibbet1@hfhs.org.

Lauren K Flynt et al. J Clin Microbiol. 2016.

. 2016 Dec 28;55(1):334-335.

doi: 10.1128/JCM.01920-16. Print 2017 Jan.

Lauren K Flynt¹, Michael P Veve^{1

2}, Linoj P Samuel¹, Robert J Tibbetts³

¹ Henry Ford Hospital, Detroit, Michigan, USA.
² Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
³ Henry Ford Hospital, Detroit, Michigan, USA rtibbet1@hfhs.org.

Retraction in

Retraction for Flynt et al., "Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam".
Flynt LK, Veve MP, Samuel LP, Tibbetts RJ. Flynt LK, et al. J Clin Microbiol. 2018 May 25;56(6):e00541-18. doi: 10.1128/JCM.00541-18. Print 2018 Jun. J Clin Microbiol. 2018. PMID: 29802235 Free PMC article. No abstract available.

No abstract available

Keywords: ceftolozane-tazobactam.

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf Accessed 2 September 2016.
1. Nathwani D, Raman G, Sulham K, Menon V. 2014. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 3:32. doi:10.1186/2047-2994-3-32. - DOI - PMC - PubMed
1. Papp-Wallace KM, Bonomo RA. 2016. New β-lactamase inhibitors in clinic. Infect Dis Clin North Am 30:441–464. doi:10.1016/j.idc.2016.02.007. - DOI - PMC - PubMed
1. Humphries RM, Hindler JA. 2016. Emerging resistance, new antimicrobial agents… but not tests! The challenge of antimicrobial susceptibility testing in the current US regulations. Clin Infect Dis 63:83–88. doi:10.1093/cid/ciw201. - DOI - PubMed
1. Burns JL, Saiman L, Whittier S, Krewinski J, Liu Z, Larone D, Marshall SA, Jones RN. 2001. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolate in cystic fibrosis patients. Diagn Microbiol Infect Dis 39:257–260. doi:10.1016/S0732-8893(01)00234-6. - DOI - PubMed